Advertisement

Picture Demy-Colton BioFuture 2021 NYC C Virtual Option 650x80px
Financing › Details

H4Orphan Pharma–Cerenis: investment, 201903–201904 excl merger negotations w Cerenis owning 59% of combined company TERMINATED 4/19

 

Period Period 2019-03-27 ï¿½ 2019-04-17
Organisations Money taker H4Orphan Pharma (FR)
  Money source Cerenis Therapeutics Holding S.A.
  Today Abionyx Pharma S.A. (Euronext Paris: ABNX)
  Group Abionyx (Group)
Products Product drug delivery technology (drug formulation technology)
  Product 2 respiratory drug
     

Cerenis Therapeutics S.A.. (4/17/19). "Press Release: Cerenis Therapeutics Has Decided to Terminate the Proposed Merger with H4Orphan Pharma". Toulouse.

Cerenis Therapeutics (FR0012616852 – CEREN – PEA PME eligible), an international biopharmaceutical company dedicated to the discovery and development of HDL-based innovative therapies for treating cardiovascular and metabolic diseases, as well as new HDL-based vectors for targeted drug delivery in the field of oncology, announces that the Board of Directors has decided to terminate the proposed merger with H4Orphan Pharma, a new French biotech company dedicated to the development of products to treat pulmonary diseases, in view of difficulties in the governance of the proposed merged company.


About CERENIS

Founded in 2005, Cerenis Therapeutics is an international biopharmaceutical company dedicated to the discovery and development of HDL-based innovative therapies. Cerenis’ expertise has translated into a rich portfolio of programs for the treatment of cardiovascular disease and associated metabolic diseases such as NAFLD and NASH as well as a HDL targeted drug delivery platform in oncology, more specifically in immuno-oncology and chemotherapy.


NewCap Investor relations
Louis-Victor Delouvrier
cerenis@newcap.eu
+33 (0)1 44 71 98 53

NewCap Media relations
Nicolas Merigeau
cerenis@newcap.eu
+33 (0)1 44 71 94 98

   
Record changed: 2019-04-17

Advertisement

Picture [iito] Plain Stupid Simple 650x80px

More documents for H4Orphan Pharma (FR)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80




» top